���˿���

Immunisation uptake rates are routinely published by age 12 months and 24 months for the full course of each individual primary and booster vaccine. Calendar year data since 1995 are available on the ISD website at: (Trends in immunisation uptake by quarter, calendar and financial year - Scotland - tables 5 and 6).

The convention for reporting childhood immunisation uptake rates in Scotland and the rest of the UK is by measuring uptake of the full course of each vaccine individually. The information is collated in this way to assess levels of protection against the spread of specific infectious diseases through the routine immunisation programme.

The Scottish Government supports the work of the British Council in Scotland and values the contribution Modern Language Assistants, as native speakers, make to the language learning experience of our pupils.

The figures available, and supplied by British Council Scotland, include independent schools and cover the period 2002-2017. Those prior to 2002 are not available. Numbers for the 2017-18 school year are not yet available.

The following table lists NHS facilities which have fully closed in each year since 2007, information on NHS facilities which have closed temporarily is not centrally available.

The services provided from these hospitals, will have been re-provided in an alternative hospital, community or primary care facility and are noted in the answer.

Over the same period, new investment was undertaken in the following clinical facilities:

��

I refer the member to the answer to question S5W-10188 on 2 August 2017. All answers to written parliamentary questions are available on the Parliament’s website, the search facility for which can be found at:

��

��

The Scottish Government does not hold this information.

��

��

I refer the member to the answer to question S5W-06745 on 24 February 2017. All answers to written parliamentary questions are available on the Parliament's website, the search facility for which can be found at

��

��

Our cancer strategy, ‘Beating Cancer: Ambition and Action’ recognises the need to reduce the variation in survival rates of different types of cancer as much as possible. The strategy is accompanied by £100 million investment, and serves as a blueprint for the future of cancer services in Scotland. We also support the national Quality Performance Indicator programme which aims to drive improvement in the outcomes and survival rates for people with cancer, including those noted by the Less Survivable Cancers Taskforce.

In 2014 to help support earlier referral or investigation of patients who may be showing a suspicion of cancer, Healthcare Improvement Scotland updated and published revised Scottish Referral Guidelines for Suspected Cancer, which cover a wide range of tumour types. These guidelines should help in the identification of peoplemost likely to have cancer and require specialist assessment. The updated version of the guidelines is available at the following Link: .

With regard to pancreatic cancer specifically, Scotland is currently the only part of the UK whose government is specifically co-funding research into pancreatic cancer along with a charity.

As part of the £4 million Precision Medicine Ecosystem Investment announced by the First Minister in February 2016, the Scottish Government has made available over £700,000 to support “Precision Panc”, a pan-Scotland study led by Professor Andrew Biankin from the University of Glasgow that uses state of the art techniques to better characterise pancreatic cancer, allowing patients to be recruited to clinical trials efficiently and quickly. In March 2017, Cancer Research UK announced an investment of £10 million to support Precision Panc. This investment will allow the molecular profiling of patients’ tumours, and help to improve our understanding of this tumour type.

��

��

The Scottish Government has provided funding for 111 continuous glucose monitoring (CGM) devices in 2017-18 as set out in Directors Letter .

We have followed the advice of the Scottish Diabetes Group (SDG) with funding allocated in 2017-18 to ensure that appropriate CGM services are established in NHS Boards across Scotland.

We will fund a higher number of CGMs in subsequent years but the approach we have taken will help ensure equality of access for those with the greatest clinical need regardless of where they live in Scotland.

��

��

I wrote to Vertex Pharmaceuticals in March to encourage them to take forward discussions about the cost of Orkambi® with colleagues in National Health Services Scotland who are best placed to advise them on pricing approaches and a fair price that could support the securing of a positive recommendation from the Scottish Medicines Consortium for the prescribing of these products in NHSScotland. Those talks are underway.

Through those discussions we hope that the manufacturer will make their best offer on price and indicate that they will re-submit an application for Orkambi® to the SMC.

��

��

The Scottish Medicines Consortium is working in collaboration with patient groups, health boards, pharmaceutical companies, the Scottish Government and other stakeholders on the review of the definitions of end-of-life, orphan and ultra-orphan medicines. This work is progressing at pace.

��

��